Multiple relapses characterize the course of disease in most patients with schizophrenia. Long-acting injectable (LAI) antipsychotics can help improve adherence to schizophrenia therapy to minimize relapse episodes. In a dinner symposium sponsored by Lundbeck, Professor Nagesh Pai of the University of Wollongong, Australia, discussed the benefits of LAI antipsychotics with focus on aripiprazole once-monthly (Abilify Maintena®) and reviewed clinical considerations for their use in schizophrenia.
Professor Pai is currently a Professor & Academic Leader of Psychiatry at the University of Wollongong and Senior Clinical Academic, Psychogeriatric services at the Illawarra Shoalhaven Local Health District.
Find out more about Professor Pai in the module.